Deutsche Bank AG Purchases 102,230 Shares of DaVita Inc. (NYSE:DVA)

Deutsche Bank AG raised its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 35.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 392,422 shares of the company's stock after purchasing an additional 102,230 shares during the period. Deutsche Bank AG owned about 0.48% of DaVita worth $58,687,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in DVA. Wellington Management Group LLP grew its holdings in DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after acquiring an additional 227 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of DaVita by 134.6% during the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock valued at $8,885,000 after purchasing an additional 31,502 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in DaVita by 201.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 74,617 shares of the company's stock valued at $11,159,000 after buying an additional 49,885 shares during the period. Hussman Strategic Advisors Inc. raised its stake in DaVita by 200.0% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 25,200 shares of the company's stock worth $3,769,000 after buying an additional 16,800 shares in the last quarter. Finally, Caprock Group LLC purchased a new stake in DaVita during the fourth quarter worth $200,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DVA. Barclays lifted their price target on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. Finally, StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $166.33.

DaVita Trading Up 0.4%

DaVita stock opened at $144.29 on Tuesday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a market cap of $11.09 billion, a PE ratio of 13.43, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The stock has a 50-day moving average of $145.93 and a two-hundred day moving average of $153.74. DaVita Inc. has a one year low of $131.44 and a one year high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The firm had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same period last year, the firm posted $2.26 EPS. DaVita's revenue was up 5.0% on a year-over-year basis. On average, research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.